

June 14, 2016



## OPKO Health to Host Analyst & Investor Day in New York City on June 15

MIAMI--(BUSINESS WIRE)-- **OPKO Health, Inc. (NYSE:OPK)** ("OPKO" or the "Company") announces that it will host an Analyst & Investor Day on Wednesday, June 15, 2016 beginning at 4:30 p.m. local time in New York City. Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health, will host the event along with other key members of OPKO Health senior management. The meeting will focus on OPKO Health's diversified business units and will provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of prostate cancer, renal disease and endocrinology will be featured speakers at the meeting.

The presentations and Q&A will be webcast live beginning at 5:00 p.m. Eastern time. The live and archived webcast will be available on the Investor Relations section of OPKO Health's corporate website at [www.opko.com](http://www.opko.com).

### **About OPKO Health, Inc.**

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism (SHPT) in stage 3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency (pending FDA approval) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation (PDUFA January 2017)). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160614006381/en/>

### **OPKO Health, Inc.**

Tara Mackay, 305-575-4100

Investor Relations

or

### **Media:**

Rooney & Associates

Terry Rooney, 212-223-0689

[trooney@rooneyco.com](mailto:trooney@rooneyco.com)

or

Marion Janic, 212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors:**

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.